Name | BRD 4354 |
---|
Description | BRD 4354 is a moderately potent inhibitor of HDAC5 and HDAC9, with IC50s of 0.85 and 1.88 μM, respectively. |
---|---|
Related Catalog | |
Target |
HDAC5:0.85 μM (IC50) HDAC9:1.88 μM (IC50) |
In Vitro | BRD 4354 is a moderately potent inhibitor of HDAC5 and HDAC9, with BRD4354 having half-maximum inhibitory concentrations (IC50) of 0.85 μM and 1.88 μM, respectively. BRD 4354 also inhibits HDACs 4, 6, 7, and 8 at higher concentrations (3.88-13.8 μM) but demonstrates less of an inhibitory effect on other class I HDACs 1, 2, and 3 (IC50>40 μM) [1]. |
Cell Assay | A549 adenocarcinoma cells were treated with BRD 4354 for 24 h at 10 μM, and the top 50 upregulated and top 50 down regulated genes are compared to other compound treatments involving drugs, bioactive compounds with established MoA, and novel synthetic compounds[1]. |
References |
Molecular Formula | C21H23ClN4O |
---|---|
Molecular Weight | 382.89 |
Storage condition | 2-8℃ |